Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calderasib + Cetuximab + mFOLFOX6 in KRAS G12C-mutant Colorectal Cancer
NCT06997497Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of calderasib in colorectal adenocarcinoma, sponsored by Merck & Co.. Started Jul 2025; status: recruiting.
02
Drugs
calderasib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT06997497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997497.